Advertisement

Neurotherapeutics

, Volume 6, Issue 3, pp 598–603 | Cite as

Current management of metastatic brain disease

  • Tulika Ranjan
  • Lauren E. Abrey
Review Article

Summary

Brain metastases are the most common intracranial tumor in adults. The incidence of metastases is thought to be rising due to better detection and treatment of systemic malignancy. More widespread use and improved quality of MRI may lead to early detection of brain metastases. Available evidence suggests that survival is longer and quality of life improved if brain metastases are treated aggressively. This article reviews current therapeutic management used for brain metastases. To select the appropriate therapy, the physician must consider the extent of the systemic disease, primary histology, and patient age and performance status, as well as the number, size, and location of the brain metastases. Available treatment options include whole-brain radiotherapy (WBRT), stereotactic radiosurgery (SRS), surgery, and chemotherapy. Multidisciplinary approaches such as the combination of WBRT with SRS or surgery have shown superior results in terms of survival time, neurocognitive function, and quality of life. The utility and optimal use of chemotherapy and radiosensitizing agents is less clear. It is hoped that further advances and multidisciplinary approaches currently under study will result in improved patient outcomes.

Key Words

Brain metastases brain metastasis chemotherapy brain metastasis radiotherapy metastatic brain tumor brain neoplasm 

References

  1. 1.
    Patchell R. Brain metastases. Handb Neurol 1997;25: 135.Google Scholar
  2. 2.
    Posner JB. Management of brain metastases. Rev Neurol (Paris) 1992;148: 477–487.Google Scholar
  3. 3.
    Sawaya R, Bindal RK. Metastatic brain tumors. 2nd ed. In: Kaye AH, Laws ER, editors. Brain tumors. Edinburgh: Churchill Livingstone; 2001: 999–1026.Google Scholar
  4. 4.
    Graus F, Walker RW, Allen JC. Brain metastases in children. J Pediatr 1983;103: 558–561.CrossRefPubMedGoogle Scholar
  5. 5.
    Wen PY, Loeffler JS. Management of brain metastases. Oncology 1999;13: 941–954.PubMedGoogle Scholar
  6. 6.
    Johnson JD, Young B. Demographics of brain metastasis. Neurosurg Clin N Am 1996;7: 337–344.PubMedGoogle Scholar
  7. 7.
    Raizer JJ, Abrey LE, editors. Brain metastases. New York: Springer, 2007.Google Scholar
  8. 8.
    Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res 2007;13: 1648–1655.CrossRefPubMedGoogle Scholar
  9. 9.
    Stemmler J, Schmitt M, Willems A, et al. Brain metastases in HER-2 overexpressing metastatic breast cancer: comparative analysis of trastuzumab levels in serum and cerebrospinal fluid. J Clin Oncol 2006;24: 64s (abstract).CrossRefGoogle Scholar
  10. 10.
    Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol 2000;18: 2349–2351.PubMedGoogle Scholar
  11. 11.
    Sirven JI, Wingerchuk DM, Drazkowski JF, Lyons MK, Zimmerman RS. Scizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc 2004;79: 1489–1494.CrossRefPubMedGoogle Scholar
  12. 12.
    Shehata MK, Young B, Reid B, et al. Stereotactic radiosurgery of 468 brain metastases ≤2 cm: implications for SRS dose and whole brain radiation therapy. Int J Radiat Oncol Biol Phys 2004;59: 87–93.CrossRefPubMedGoogle Scholar
  13. 13.
    Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998;280: 1485–1489.CrossRefPubMedGoogle Scholar
  14. 14.
    Caimcross JG, Kim JH, Posner JB. Radiation therapy for brain metastases. Ann Neurol 1980;7: 529–541.CrossRefGoogle Scholar
  15. 15.
    Byrne TN, Cascino TL, Posner JB. Brain metastasis from melanoma. J Neurooncol 1983;1: 313–317.CrossRefPubMedGoogle Scholar
  16. 16.
    Cascino TL, Leavengood JM, Kemeny N, Posner JB. Brain metastases from colon cancer. J Neurooncol 1983;1: 203–209.CrossRefPubMedGoogle Scholar
  17. 17.
    Gay PC, Litchy WJ, Cascino TL. Brain metastasis in hypernephroma. J Neurooncol 1987;5: 51–56.CrossRefPubMedGoogle Scholar
  18. 18.
    Li J, Bentzen SM, Renschler M, Mehta MP. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol 2007;25: 1260–1266.CrossRefPubMedGoogle Scholar
  19. 19.
    Rades D, Haatanen T, Schild SE. Dose escalation beyond 30 grays in 10 fractions for patients with multiple brain metastases. Cancer 2007;110: 1345–1350.CrossRefPubMedGoogle Scholar
  20. 20.
    Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;37: 745–751.CrossRefPubMedGoogle Scholar
  21. 21.
    Kurtz JM, Gelber R, Brady LW, Carella RJ, Cooper JS; Radiation Therapy Oncology Group. The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1981;7: 891–895.CrossRefPubMedGoogle Scholar
  22. 22.
    Mehta MP, Rodrigus P, Terhaard CH, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003;21: 2529–2536.CrossRefPubMedGoogle Scholar
  23. 23.
    Suh JH, Stea B, Nabid A, et al. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol 2006;24: 106–114.CrossRefPubMedGoogle Scholar
  24. 24.
    Cerchietti LC, Bonomi MR, Navigante AH, Castro MA, Cabalar ME, Roth BM. Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases. J Neurooncol 2005;71: 73–81.CrossRefPubMedGoogle Scholar
  25. 25.
    Tishler RB, Schiff PB, Geard CR, Hall EJ. Taxol: a novel radiation sensitizer. Cancer Res 1992;52: 3495–3497.PubMedGoogle Scholar
  26. 26.
    DeAngelis LM, Currie VE, Kim JH, et al. The combined use of radiation therapy and lonidamine in the treatment of brain metastases. J Neurooncol 1989;7: 241–247.CrossRefPubMedGoogle Scholar
  27. 27.
    Eyre HJ, Ohlsen JD, Frank J, et al; Southwest Oncology Group Randomized trial of radiotherapy versus radiotherapy plus metronidazole for the treatment metastatic cancer to brain. A Southwest Oncology Group study. J Neurooncol 1984;2: 325–330.CrossRefPubMedGoogle Scholar
  28. 28.
    Komarnicky LT, Phillips TL, Martz K, Asbell S, Isaacson S, Urtasun R. A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int J Radiat Oncol Biol Phys 1991;20: 53–58.CrossRefPubMedGoogle Scholar
  29. 29.
    Phillips TL, Scott CB, Leibel SA, Rotman M, Weigensberg IJ. Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: report of RTOG trial 89-05. Int J Radiat Oncol Biol Phys 1995;33: 339–348.CrossRefPubMedGoogle Scholar
  30. 30.
    Conill C, Berenguer J, Vargas M, et al. Incidence of radiation-induced leukoencephalopathy after whole brain radiotherapy in patients with brain metastases. Clin Transl Oncol 2007;9: 590–595.CrossRefPubMedGoogle Scholar
  31. 31.
    DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology 1989;39: 789–796.PubMedGoogle Scholar
  32. 32.
    Simonová G, Liscák R, Novotný J Jr, Novotný J. Solitary brain metastases treated with the Leksell gamma knife: prognostic factors for patients. Radiother Oncol 2000;57: 207–213.CrossRefPubMedGoogle Scholar
  33. 33.
    Vogelbaum MA, Angelov L, Lee SY, Li L, Barnett GH, Suh JH. Local control of brain metastases by stereotactic radiosurgery in relation to dose to the tumor margin. J Neurosurg 2006;104: 907–912.CrossRefPubMedGoogle Scholar
  34. 34.
    Varlotto JM, Flickinger JC, Niranjan A, Bhatnagar AK, Kondziolka D, Lunsford LD. Analysis of tumor control and toxicity in patients who have survived at least one year after radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 2003;57: 452–464.CrossRefPubMedGoogle Scholar
  35. 35.
    Xu N, Shu H, Marcus R, Crocker IR. Radiation necrosis after stereotactic radiosurgery for metastatic brain disease. Int J Radiat Oncol Biol Phys 2007;69: S163 (abstract).Google Scholar
  36. 36.
    Müller-Riemenschneider F, Bockelbrink A, et al. Stereotactic radiosurgery for the treatment of brain metastases. Radiother Oncol 2009;91: 67–74.CrossRefPubMedGoogle Scholar
  37. 37.
    Moser RP, Johnson ML, Surgical management of brain metastases: how aggressive should we be? Oncology 1989;3: 123–127.PubMedGoogle Scholar
  38. 38.
    Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322: 494–500.CrossRefPubMedGoogle Scholar
  39. 39.
    Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 1993;33: 583–590.CrossRefPubMedGoogle Scholar
  40. 40.
    Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996;78: 1470–1476.CrossRefPubMedGoogle Scholar
  41. 41.
    Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004;363: 1665–1672.CrossRefPubMedGoogle Scholar
  42. 42.
    Kondziolka D, Patel A, Lunsford LD, et al. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 1999;45: 427–434.PubMedGoogle Scholar
  43. 43.
    Huang K, Sneed PK, Kunwar S, et al. Surgical resection and permanent iodine-125 brachytherapy for brain metastases. J Neurooncol 2009;91: 83–93.CrossRefPubMedGoogle Scholar
  44. 44.
    Ewend MG, Brem S, Gilbert M, et al. Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control. Clin Cancer Res 2007;13: 3637–3641.CrossRefPubMedGoogle Scholar
  45. 45.
    Cortot AB, Gerinière L, Robinet G, et al. Groupe Lyon-Saint-Etienne d’Oncologie Thoracique; Groupe Français de Pneumo-Cancérologie. Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study. Ann Oncol 2006;17: 1412–1417.CrossRefPubMedGoogle Scholar
  46. 46.
    Wu C, Li YL, Wang ZM, Li Z, Zhang TX, Wei Z. Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer 2007;57: 359–364.CrossRefPubMedGoogle Scholar
  47. 47.
    Chiu CH, Tsai CM, Chen YM, Chiang SC, Liou JL, Perng RP. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer 2005;47: 129–138.CrossRefPubMedGoogle Scholar
  48. 48.
    Bernardo G, Cuzzoni Q, Strada MR, et al. First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a phase II study. Cancer Invest 2002;20: 293–302.CrossRefPubMedGoogle Scholar
  49. 49.
    Fujita A, Fukuoka S, Takabatake H, Tagaki S, Sekine K. Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer. Oncology 2000;59: 291–295.CrossRefPubMedGoogle Scholar
  50. 50.
    Rosner D, Nemoto T, Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986;58: 832–839.CrossRefPubMedGoogle Scholar
  51. 51.
    Boogerd W, Dalesio O, Bais EM, van der Sande JJ. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 1992;69: 972–978.CrossRefPubMedGoogle Scholar
  52. 52.
    Franciosi V, Cocconi G, Michiara M, et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, non-small cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999;85: 1599–1605.CrossRefPubMedGoogle Scholar
  53. 53.
    Abrey LE, Olson JD, Raizer JJ, et al. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 2001;53: 259–265.CrossRefPubMedGoogle Scholar
  54. 54.
    Lassman AB, Abrey LE, Shah GD, et al. Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol 2006;78: 255–260.CrossRefPubMedGoogle Scholar
  55. 55.
    Ron IG, Sarid D, Ryvo L, et al. A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study. Melanoma Res 2006;16: 65–69.CrossRefPubMedGoogle Scholar
  56. 56.
    Atkins MB, Sosman JA, Agarwala S, et al. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer 2008;113: 2139–2145.CrossRefPubMedGoogle Scholar
  57. 57.
    Bafaloukos D, Tsoutsos D, Fountzilas G, et al. The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma. Melanoma Res 2004;14: 289–294.CrossRefPubMedGoogle Scholar

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2009

Authors and Affiliations

  1. 1.Department of NeurologyMemorial Sloan-Kettering Cancer CenterNew York

Personalised recommendations